Institutional shares held 627 Million
27.9M calls
21.8M puts
Total value of holdings $10.5B
$468M calls
$366M puts
Market Cap $18.4B
1,110,560,000 Shares Out.
Institutional ownership 56.42%
# of Institutions 660


Latest Institutional Activity in TEVA

Top Purchases

Q1 2025
Harel Insurance Investments & Financial Services Ltd. Shares Held: 22.1M ($365M)
Q1 2025
Rubric Capital Management LP Shares Held: 25.6M ($423M)
Q1 2025
Glenview Capital Management, LLC Shares Held: 14.8M ($245M)
Q1 2025
Phoenix Holdings Ltd. Shares Held: 27.5M ($455M)
Q1 2025
Duquesne Family Office LLC Shares Held: 14.9M ($246M)

Top Sells

Q1 2025
Goldman Sachs Group Inc Shares Held: 3.97M ($65.6M)
Q1 2025
Morgan Stanley Shares Held: 11M ($182M)
Q1 2025
Noked Israel LTD Shares Held: 210K ($3.47M)
Q1 2025
Driehaus Capital Management LLC Shares Held: 18.6K ($308K)
Q1 2025
D. E. Shaw & Co., Inc. Shares Held: 81.2K ($1.34M)

About TEVA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.


Insider Transactions at TEVA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.66M Shares
From 19 Insiders
Exercise of conversion of derivative security 1.66M shares
Sell / Disposition
2.03M Shares
From 9 Insiders
Open market or private sale 2.03M shares

Track Institutional and Insider Activities on TEVA

Follow TEVA PHARMACEUTICAL INDUSTRIES LTD and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TEVA shares.

Notify only if

Insider Trading

Get notified when an Teva Pharmaceutical Industries LTD insider buys or sells TEVA shares.

Notify only if

News

Receive news related to TEVA PHARMACEUTICAL INDUSTRIES LTD

Track Activities on TEVA